Iterative Development and Evaluation of a Pharmacogenomic-Guided Clinical Decision Support System for Warfarin Dosing

Summary Objective Pharmacogenomic-guided dosing has the potential to improve patient outcomes but its implementation has been met with clinical challenges. Our objective was to develop and evaluate a clinical decision support system (CDSS) for pharmacogenomic-guided warfarin dosing designed for phys...

Full description

Saved in:
Bibliographic Details
Published in:Applied clinical informatics 2016-11, Vol.7 (4), p.1088-1106
Main Authors: Melton, Brittany L., Zillich, Alan J., Saleem, Jason J., Russ, Alissa L., Tisdale, James E., Overholser, Brian R.
Format: Article
Language:English
Subjects:
Decision Support Systems, Clinical
Drug Dosage Calculations
Drug Prescriptions
Female
Humans
Male
Pharmacogenetics
Research Article
Warfarin - pharmacology
Warfarin - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Objective Pharmacogenomic-guided dosing has the potential to improve patient outcomes but its implementation has been met with clinical challenges. Our objective was to develop and evaluate a clinical decision support system (CDSS) for pharmacogenomic-guided warfarin dosing designed for physicians and pharmacists. Methods Twelve physicians and pharmacists completed 6 prescribing tasks using simulated patient scenarios in two iterations (development and validation phases) of a newly developed pharmacogenomic-driven CDSS prototype. For each scenario, usability was measured via efficiency, recorded as time to task completion, and participants’ perceived satisfaction which were compared using Kruskal-Wallis and Mann Whitney U tests, respectively. Debrief interviews were conducted and qualitatively analyzed. Usability findings from the first (i.e. development) iteration were incorporated into the CDSS design for the second (i.e. validation) iteration. Results During the CDSS validation iteration, participants took more time to complete tasks with a median (IQR) of 183 (124–247) seconds versus 101 (73.5–197) seconds in the development iteration (p=0.01). This increase in time on task was due to the increase in time spent in the CDSS corresponding to several design changes. Efficiency differences that were observed between pharmacists and physicians in the development iteration were eliminated in the validation iteration. The increased use of the CDSS corresponded to a greater acceptance of CDSS recommended doses in the validation iteration (4% in the first iteration vs. 37.5% in the second iteration, p
ISSN:1869-0327
1869-0327
DOI:10.4338/ACI-2016-05-RA-0081